Asthma Drugs Market
Asthma Drugs Market Size, Share & Trends Analysis Report by Drug Class (Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, and Combination Drugs), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast Period (2026–2035)
Industry Overview
Asthma drugs market was valued at $27.5 billion in 2025 and is projected to reach $47.6 billion by 2035, growing at a CAGR of 5.7% during the forecast period (2026-2035). The market is expanding steadily, supported by the rising prevalence of respiratory conditions across both developed and emerging economies. Increased diagnosis rates and improved access to healthcare services are contributing to higher treatment adoption. Advancements in targeted therapies, particularly biologics, are enhancing clinical outcomes and driving higher-value prescriptions. Continued innovation in combination therapies and inhalation-based drug delivery systems is further strengthening market demand. In addition, supportive regulatory frameworks and growing awareness of long-term disease management are sustaining consistent market growth.
Market Dynamics
Increasing Disease Prevalence and Shift toward Long-Term Management
The asthma drugs market is primarily driven by the sustained increase in diagnosed asthma cases and the shift toward long-term disease management. Higher awareness among patients and clinicians has led to earlier diagnosis and consistent use of maintenance therapies, particularly inhaled corticosteroids and combination treatments. Clinical guidelines increasingly emphasize preventive care over episodic treatment, which supports recurring prescription volumes. In addition, urban exposure to environmental pollutants and allergens continues to influence disease incidence, reinforcing the need for continuous pharmacological intervention. Expanding healthcare coverage and improved access to essential medicines across developing regions are further enabling steady uptake of standard and advanced therapies.
Advancements in Biologic Therapies and Targeted Drug Development
Another significant driver is the growing adoption of biologic therapies for moderate to severe asthma, supported by strong clinical efficacy and targeted mechanisms of action. Pharmaceutical companies are prioritizing research in monoclonal antibodies that address specific inflammatory pathways, resulting in premium-priced products with sustained demand. The increasing availability of these therapies through specialist care settings is improving treatment outcomes for patients who are unresponsive to conventional drugs. At the same time, ongoing innovation in inhalation technologies and fixed-dose combination drugs is enhancing patient compliance and therapeutic effectiveness. Regulatory support for novel drug approvals and lifecycle management strategies is also contributing to a stable pipeline, ensuring continued market expansion.
Market Segmentation
- Based on the drug class, the market is segmented into bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs.
- Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Monoclonal Antibodies Emerging as a High-Growth Therapeutic Segment
Monoclonal antibodies represent one of the fastest-expanding segments due to their targeted action in managing moderate to severe asthma cases. Their clinical effectiveness in reducing exacerbations and hospitalizations has strengthened physician preference in specialist settings. Leading companies such as AstraZeneca plc, Sanofi S.A., and Regeneron Pharmaceuticals, Inc. are actively advancing biologic portfolios. Recent trends indicate increased approvals of pathway-specific therapies focusing on eosinophilic and allergic asthma. Higher pricing and strong reimbursement support are contributing to revenue concentration within this segment. Continued pipeline expansion is expected to sustain its accelerated growth trajectory.
Retail Pharmacies Maintaining Dominance in Drug Dispensation Channels
Retail pharmacies account for the largest share of distribution due to their accessibility and established role in chronic disease management. Patients rely on these outlets for regular refills of maintenance medications, particularly inhalers and oral therapies. Key manufacturers such as GlaxoSmithKline plc and Teva Pharmaceutical Industries Ltd. maintain strong retail distribution networks. The increasing availability of generic drugs has further strengthened volume sales through this channel. Recent trends show integration with digital prescription systems, improving convenience and adherence. Consistent demand for long-term therapies ensures stable growth within this segment.
Regional Outlook
The global asthma drugs market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Demonstrating Strong Adoption of Advanced Asthma Therapies
North America continues to show steady growth, supported by high diagnosis rates and structured treatment protocols. The region benefits from the strong presence of major pharmaceutical companies such as AstraZeneca plc and Regeneron Pharmaceuticals, Inc. Increased uptake of biologic therapies is a key contributor, particularly in severe asthma management. Favorable reimbursement frameworks are enabling wider patient access to premium treatments. Ongoing product approvals and lifecycle extensions are sustaining competitive activity. Digital prescription systems and patient monitoring tools are also improving treatment adherence across the region.
Asia-Pacific Emerging as a High-Growth Region with Expanding Treatment Access
Asia-Pacific is witnessing notable expansion due to rising disease burden and improving healthcare infrastructure. Countries such as India and China are contributing significantly to volume growth through increased access to essential medications. Companies, including Cipla Limited and Sun Pharmaceutical Industries Limited, are strengthening their regional presence. The growing availability of cost-effective generic drugs is supporting wider adoption among patients. Recent trends indicate the gradual entry of advanced therapies alongside conventional treatments. Expanding retail pharmacy networks and awareness initiatives are further driving consistent market growth.
Market Players Outlook
The major companies operating in the global asthma drugs market include GlaxoSmithKline plc, AstraZeneca plc, Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In December 2025, GlaxoSmithKline plc received approval for depemokimab (Exdensur) for severe asthma. This therapy requires only two doses per year, significantly improving patient adherence.
- In March 2025, Depemokimab became the first ultra-long-acting biologic in asthma treatment. The innovation is expected to reshape treatment protocols by reducing injection frequency and improving compliance.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global asthma drugs market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
• Global Asthma Drugs Market Sales Analysis – Drug Class | Distribution Channel | Country ($ Million)
• Asthma Drugs Market Sales Performance of Top Countries
1.1 Research Methodology
- Primary Research Approach
• Secondary Research Approach
1.2 Market Snapshot
- Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
??2.2.1 Key Asthma Drugs Market Trends
??2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Asthma Drugs Market
??2.3.1 Competitive Rivalry
??2.3.2 Threat of New Entrants
??2.3.3 Bargaining Power of Suppliers
??2.3.4 Bargaining Power of Buyers
??2.3.5 Threat of Substitutes
- Market Determinants
3.1 Market Drivers
??3.1.1 Drivers For Global Asthma Drugs Market: Impact Analysis
3.2 Market Pain Points and Challenges
??3.2.1 Restraints For Global Asthma Drugs Market: Impact Analysis
3.3 Market Opportunities
??3.3.1 Opportunities For Global Asthma Drugs Market: Impact Analysis
- Competitive Landscape
4.1 Competitive Dashboard – Asthma Drugs Market Revenue and Share by Manufacturers
- Asthma Drugs Product Comparison Analysis
• Top Market Player Ranking Matrix
4.2 Key Company Analysis
??4.2.1 GlaxoSmithKline plc
????4.2.1.1 Overview
????4.2.1.2 Product Portfolio
????4.2.1.3 Financial Analysis
????4.2.1.4 SWOT Analysis
????4.2.1.5 Business Strategy
??4.2.2 AstraZeneca plc
????4.2.2.1 Overview
????4.2.2.2 Product Portfolio
????4.2.2.3 Financial Analysis
????4.2.2.4 SWOT Analysis
????4.2.2.5 Business Strategy
??4.2.3 Novartis AG
????4.2.3.1 Overview
????4.2.3.2 Product Portfolio
????4.2.3.3 Financial Analysis
????4.2.3.4 SWOT Analysis
????4.2.3.5 Business Strategy
??4.2.4 Sanofi S.A.
????4.2.4.1 Overview
????4.2.4.2 Product Portfolio
????4.2.4.3 Financial Analysis
????4.2.4.4 SWOT Analysis
????4.2.4.5 Business Strategy
??4.2.5 Teva Pharmaceutical Industries Ltd.
????4.2.5.1 Overview
????4.2.5.2 Product Portfolio
????4.2.5.3 Financial Analysis
????4.2.5.4 SWOT Analysis
????4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
??4.3.1 Merger and Acquisition
??4.3.2 Product Launch
??4.3.3 Partnership And Collaboration
- Global Asthma Drugs Market Sales Analysis by Drug Class ($ Million)
5.1 Bronchodilators
5.2 Anti-Inflammatory Drugs
5.3 Monoclonal Antibodies
5.4 Combination Drugs
- Global Asthma Drugs Market Sales Analysis by Distribution Channel ($ Million)
6.1 Hospital Pharmacies
6.2 Retail Pharmacies
6.3 Online Pharmacies
- Regional Analysis
???7.1 North American Asthma Drugs Market Sales Analysis – Drug Class | Distribution Channel | Country ($ Million)
?????7.1.1 United States
?????7.1.2 Canada
???7.2 European Asthma Drugs Market Sales Analysis – Drug Class | Distribution Channel | Country ($ Million)
?????7.2.1 UK
?????7.2.2 Germany
?????7.2.3 Italy
?????7.2.4 Spain
?????7.2.5 France
?????7.2.6 Russia
?????7.2.7 Rest of Europe
???7.3 Asia-Pacific Asthma Drugs Market Sales Analysis – Drug Class | Distribution Channel | Country ($ Million)
?????7.3.1 China
?????7.3.2 Japan
?????7.3.3 South Korea
?????7.3.4 India
?????7.3.5 Australia & New Zealand
?????7.3.6 ASEAN Countries
?????7.3.7 Rest of Asia-Pacific
???7.4 Rest of the World Asthma Drugs Market Sales Analysis – Drug Class | Distribution Channel | Country ($ Million)
?????7.4.1 Latin America
?????7.4.2 Middle East and Africa
- Company Profiles
???8.1 ALK-Abelló A/S
????8.1.1 Quick Facts
????8.1.2 Company Overview
????8.1.3 Product Portfolio
????8.1.4 Business Strategies
???8.2 Amgen Inc.
????8.2.1 Quick Facts
????8.2.2 Company Overview
????8.2.3 Product Portfolio
????8.2.4 Business Strategies
???8.3 AstraZeneca plc
????8.3.1 Quick Facts
????8.3.2 Company Overview
????8.3.3 Product Portfolio
????8.3.4 Business Strategies
???8.4 Boehringer Ingelheim International GmbH
????8.4.1 Quick Facts
????8.4.2 Company Overview
????8.4.3 Product Portfolio
????8.4.4 Business Strategies
???8.5 Chiesi Farmaceutici S.p.A.
????8.5.1 Quick Facts
????8.5.2 Company Overview
????8.5.3 Product Portfolio
????8.5.4 Business Strategies
???8.6 Cipla Limited
???8.7 Dr. Reddy’s Laboratories Limited
???8.8 Glenmark Pharmaceuticals Limited
???8.9 GlaxoSmithKline plc
???8.10 Hanmi Pharmaceutical Co., Ltd.
???8.11 Kyorin Pharmaceutical Co., Ltd.
???8.12 Lupin Limited
???8.13 Merck & Co., Inc.
???8.14 Novartis AG
???8.15 Orion Corporation
???8.16 Pfizer Inc.
???8.17 Regeneron Pharmaceuticals, Inc.
???8.18 Roche Holding AG
???8.19 Sanofi S.A.
???8.20 Sumitomo Pharma Co., Ltd.
???8.21 Sun Pharmaceutical Industries Limited
???8.22 Teva Pharmaceutical Industries Ltd.
???8.23 Viatris Inc.
???8.24 Vectura Group plc (Philip Morris International)
???8.25 Zydus Lifesciences Limited
1. Global Asthma Drugs Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
2. Global Bronchodilators Asthma Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Anti-Inflammatory Drugs Asthma Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Monoclonal Antibodies Asthma Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Combination Drugs Asthma Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Asthma Drugs Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
7. Global Asthma Drugs Sales Via Hospital Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Asthma Drugs Sales Via Retail Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Asthma Drugs Sales Via Online Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Asthma Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
11. North America Asthma Drugs Market Research and Analysis by Country, 2025–2035 ($ Million)
12. North America Asthma Drugs Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
13. North America Asthma Drugs Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
14. Europe Asthma Drugs Market Research and Analysis by Country, 2025–2035 ($ Million)
15. Europe Asthma Drugs Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
16. Europe Asthma Drugs Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
17. Asia-Pacific Asthma Drugs Market Research and Analysis by Country, 2025–2035 ($ Million)
18. Asia-Pacific Asthma Drugs Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
19. Asia-Pacific Asthma Drugs Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
20. Rest of the World Asthma Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
21. Rest of the World Asthma Drugs Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
22. Rest of the World Asthma Drugs Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
1. Global Asthma Drugs Market Share by Drug Class, 2025 Vs 2035 (%)
2. Global Bronchodilators Asthma Drugs Market Share by Region, 2025 Vs 2035 (%)
3. Global Anti-Inflammatory Drugs Asthma Drugs Market Share by Region, 2025 Vs 2035 (%)
4. Global Monoclonal Antibodies Asthma Drugs Market Share by Region, 2025 Vs 2035 (%)
5. Global Combination Drugs Asthma Drugs Market Share by Region, 2025 Vs 2035 (%)
6. Global Asthma Drugs Market Share by Distribution Channel, 2025 Vs 2035 (%)
7. Global Asthma Drugs Sales Via Hospital Pharmacies Market Share by Region, 2025 Vs 2035 (%)
8. Global Asthma Drugs Retail Pharmacies Market Share by Region, 2025 Vs 2035 (%)
9. Global Asthma Drugs Sales Via Online Pharmacies Market Share by Region, 2025 Vs 2035 (%)
10. Global Asthma Drugs Market Share by Region, 2025 Vs 2035 (%)
11. United States Asthma Drugs Market Size, 2025–2035 ($ Million)
12. Canada Asthma Drugs Market Size, 2025–2035 ($ Million)
13. UK Asthma Drugs Market Size, 2025–2035 ($ Million)
14. France Asthma Drugs Market Size, 2025–2035 ($ Million)
15. Germany Asthma Drugs Market Size, 2025–2035 ($ Million)
16. Italy Asthma Drugs Market Size, 2025–2035 ($ Million)
17. Spain Asthma Drugs Market Size, 2025–2035 ($ Million)
18. Russia Asthma Drugs Market Size, 2025–2035 ($ Million)
19. India Asthma Drugs Market Size, 2025–2035 ($ Million)
20. China Asthma Drugs Market Size, 2025–2035 ($ Million)
21. Japan Asthma Drugs Market Size, 2025–2035 ($ Million)
22. South Korea Asthma Drugs Market Size, 2025–2035 ($ Million)
23. Australia & New Zealand Asthma Drugs Market Size, 2025–2035 ($ Million)
24. ASEAN Asthma Drugs Market Size, 2025–2035 ($ Million)
25. Rest of Asia-Pacific Asthma Drugs Market Size, 2025–2035 ($ Million)
26. Latin America Asthma Drugs Market Size, 2025–2035 ($ Million)
27. Middle East & Africa Asthma Drugs Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
